ImmuCell (ICCC) Stock Price
ImmuCell Price
Revenue has compounded at 9.7% per year over the past 19 years to 27.64 M USD. Earnings per share have declined at 7.3% per year over the last 10 years. ImmuCell's net margin stands at -3.8%, down from -0.4% several years earlier.
ImmuCell stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
ImmuCell business model & stock analysis
Frequently asked questions about ImmuCell
ImmuCell Corp operates as a biotechnology company, focusing on the development and commercialization of products that improve the health and productivity of dairy and beef cattle. The company's business model revolves around providing innovative animal health solutions, such as First Defense® for newborn calves, which helps strengthen their immune system and prevent diseases. ImmuCell Corp also offers Mast Out®, an FDA-approved treatment for mastitis in lactating dairy cows. Through its dedication to science-driven research and development, ImmuCell Corp aims to enhance animal well-being, increase farmers' efficiency, and ultimately contribute to a sustainable agriculture industry.
ImmuCell Corp is primarily active in the animal health industry.
The main competitors of ImmuCell Corp in the market include companies such as Zoetis Inc., Elanco Animal Health Inc., and Merck & Co. Inc.
ImmuCell Corp is a renowned biotechnology company specializing in the development and production of innovative, preventative animal health products, focusing primarily on the dairy and beef industries. Founded in 1982 and headquartered in Portland, Maine, ImmuCell has established itself as a leader in the field of animal health through its dedication to improving the well-being and productivity of livestock. The company's flagship product, First Defense®, helps protect newborn calves against common diseases while enhancing their natural immune system. ImmuCell Corp remains committed to research and development, continuously striving to provide cutting-edge solutions for animal health challenges.
ImmuCell Corp has achieved significant milestones in its history. One of the notable accomplishments is the development and commercialization of their flagship product, First Defense®. This groundbreaking product has revolutionized the field of animal health by providing a proactive approach to preventing calf scours. Additionally, ImmuCell Corp has successfully expanded its product portfolio to include prominent offerings such as Wipe Out® Dairy Wipes and California Mastitis Test. The company's commitment to research and innovation has garnered recognition, including the prestigious "Best Places to Work in Maine" award. ImmuCell Corp continues to make strides in the animal health industry, solidifying its position as a leader in innovative solutions that enhance herd productivity and profitability.
ImmuCell Corp is primarily present in the United States.
ImmuCell Corp represents a set of core values and a corporate philosophy aimed at advancing animal health and well-being. The company is committed to developing, manufacturing, and selling products that enhance the health and productivity of animals, with a specific focus on the dairy and beef industries. ImmuCell prioritizes quality, innovation, and sustainability, striving to provide effective solutions for preventing and treating various diseases. By leveraging their expertise in animal health, ImmuCell Corp aims to contribute to healthier livestock populations and more efficient farming practices.
7 analysts currently rate the ImmuCell stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect ImmuCell to generate revenue of 15.14 M USD and earnings per share of -0.24 USD.
Converted at the current exchange rate, the ImmuCell share trades at 8.75 EUR (9.80 USD).
The ImmuCell share (ICCC) is listed on 2 stock exchanges, including: NASDAQ (ICCC), Frankfurt (IUL.F).
ImmuCell Corp is a US company specializing in the development and marketing of products for the prevention and treatment of animal diseases, particularly in the dairy industry. The company operates in two main divisions: animal health and veterinary diagnostics. In the animal health division, the flagship product is Calf-Guard®, an immunoglobulin preparation used for preventing diarrhea in calves. In the veterinary diagnostics division, the Bovine IgG Rapid Test Kit is a key product that allows farmers to monitor the health of their animals and detect diseases in a timely manner. ImmuCell Corp aims to expand its product pipeline and enter new markets.
The expected revenue of ImmuCell is 15.14 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of ImmuCell is -2.17 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of ImmuCell is currently -40.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ImmuCell stock.
The price-to-sales ratio (P/S) of ImmuCell is currently 5.86. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ImmuCell stock.
The Eulerpool Quality Score for ImmuCell is 3/10.
The ISIN of ImmuCell is US4525253062. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of ImmuCell is 885825. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of ImmuCell is ICCC. The ticker symbol is used to trade ImmuCell shares on the stock exchange.
ImmuCell stock
ImmuCell Peer Group
ImmuCell Ticker
ImmuCell FIGI
All fundamentals and in-depth analysis of ImmuCell
Our stock analysis for ImmuCell stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuCell. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.